ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes - Top-Institutions - MDSpire

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

  • By

  • Shaoqing Yin

  • Jiaye Li

  • Wei Zhang

  • Rui Ding

  • Yan Li

  • Kai Wang

  • Wenjian Jiang

  • Yi-Da Tang

  • Zhengjun Yi

  • Yaohua Zhang

  • Meng Li

  • June 17, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Broad Institute of MIT and Harvard with Massachusetts General Hospital
    Broad Institute of MIT and Harvard with Massachusetts General Hospital

    Cambridge, Massachusetts

    Key Differentiators

    • Genetics
    • Genomic Medicine

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology
    • Genetics

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Genetics
    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Genetics

  • #5

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, Tennessee

    Key Differentiators

    • Pediatric Oncology
    • Genetics

Original Source(s)

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

  • by Shaoqing Yin, Jiaye Li, Wei Zhang, Rui Ding, Yan Li, Kai Wang, Wenjian Jiang, Yi-Da Tang, Zhengjun Yi, Yaohua Zhang, Meng Li

  • June 17, 2026

Related Content

Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

  • by

  • May 29, 2026

  • 5 min
Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia